ClinicalTrials.gg
CompletedNCT00121810Updated Apr 15, 2011Results posted

Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients

A Phase 4 interventional study of mycophenolate mofetil [CellCept] and Corticosteroids in Kidney Transplantation, sponsored by Hoffmann-La Roche. Completed at 36 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-04-15.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
305
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This 2-arm study recruited kidney transplant patients who were receiving standard care of calcineurin inhibitors (CNIs, tacrolimus or cyclosporine), CellCept (1.0-1.5 g twice daily) and corticosteroids. They were either randomized to continue this regimen, or CNI therapy was discontinued and replaced by sirolimus therapy (in combination with CellCept and corticosteroids). The effect of these 2 regimens on efficacy, safety and kidney function was evaluated. The anticipated time on study treatment was 1-2 years, and the target sample size was 100-500 individuals.

02

Conditions studied

  • Kidney Transplantation
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients 18-75 years of age
  • Kidney transplant 30-180 days post-transplantation
  • Receipt of cyclosporine or tacrolimus, CellCept, and for greater than 14 days prior to study entry
  • No known to sirolimus

Exclusion criteria

Exclusion Criteria:

  • Multiple organ transplant recipients or secondary kidney transplant recipients
  • -resistant rejection episode within 90 days prior to study entry or corticosteroid-sensitive rejection episode within 30 days prior to study entry
  • More than 1 -proven episode of acute rejection prior to study entry
  • Treated with sirolimus before the study
  • Organ transplant or expected organ transplant, other than kidney
  • History of in the last 5 years (except successfully treated localized non-melanotic skin cancer)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
305 participants (actual)

Study arms

  • Experimental
    1

    Drug: mycophenolate mofetil [CellCept] · Drug: Corticosteroids · Drug: Sirolimus

  • Active comparator
    2

    Drug: mycophenolate mofetil [CellCept] · Drug: Corticosteroids · Drug: Calcineurin inhibitors

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Percent Change in Glomerular Filtration Rate From Baseline to Month 12

    The primary efficacy endpoint was mean percent change in renal function from baseline to 12 months postrandomization, as measured by Glomerular Filtration Rate utilizing renal clearance of cold iothalamate. percent change= \[(Glomerular Filtration Rate at Month 12-Glomerular Filtration Rate at baseline)/Glomerular Filtration Rate at baseline\]\*100 percent.

    Time frame: baseline to 12 months

Secondary outcomes

  1. Mean Percent Change in Glomerular Filtration Rate From Baseline to Month 24

    A secondary efficacy endpoint was mean percent change in renal function from baseline to 24 months postrandomization, as measured by Glomerular Filtration Rate utilizing renal clearance of cold iothalamate. percent change= \[(Glomerular Filtration Rate at Month 24-Glomerular Filtration Rate at baseline)/Glomerular Filtration Rate at baseline\]\*100 percent.

    Time frame: Baseline to 24 months

  2. Mean Percent Change in Serum Creatinine From Baseline to Months 6, 12, and 24

    Renal allograft function determined by mean percent change from baseline in serum creatinine by treatment group at 6, 12, and 24 months postrandomization. percent change= \[(serum creatinine at Month t-serum creatinine at baseline)/serum creatinine at baseline\]\*100 percent, where t=6, 12, and 24 months postrandomization.

    Time frame: baseline, 6, 12, and 24 months

  3. Mean Percent Change in Calculated Creatinine Clearance From Baseline to Months 6, 12, and 24

    Renal allograft function determined by mean percent change from baseline in calculated creatinine clearance (Cockroft and Gault method) by treatment group at 6, 12, and 24 months postrandomization. percent change= \[(calculated creatinine clearance at Month t - calculated creatinine clearance at baseline)/calculated creatinine clearance at baseline\]\*100 percent, where t=6, 12, and 24 months postrandomization

    Time frame: baseline 6, 12, and 24 months

  4. Mean Percent Change in Calculated Glomerular Filtration Rate From Baseline to Months 6, 12, and 24 (Nankivell Equation)

    Renal allograft function determined by mean percent change from baseline in calculated Glomerular Filtration Rate (Nankivell equation) by treatment group at 6, 12, and 24 months postrandomization. percent change= \[(calculated Glomerular Filtration Rate at Month t - calculated Glomerular Filtration Rate at baseline)/calculated Glomerular Filtration Rate at baseline\]\*100 percent, where t=6, 12, and 24 months postrandomization.

    Time frame: baseline, 6, 12, and 24 months

07

Results

Posted Feb 24, 2011

Participant flow

Participant flow — Overall Study
MilestoneMycophenolate Mofetil + SirolimusMycophenolate Mofetil + Cyclosporine or Tacrolimus
Started151154
Safety population148153
Intent-to-treat (itt) population148151
Completed121115
Not completed3039

Outcome measures

PrimaryMean Percent Change in Glomerular Filtration Rate From Baseline to Month 12

The primary efficacy endpoint was mean percent change in renal function from baseline to 12 months postrandomization, as measured by Glomerular Filtration Rate utilizing renal clearance of cold iothalamate. percent change= \[(Glomerular Filtration Rate at Month 12-Glomerular Filtration Rate at baseline)/Glomerular Filtration Rate at baseline\]\*100 percent.

Time frame:
baseline to 12 months
Reported as:
Mean · percent change
Mean Percent Change in Glomerular Filtration Rate From Baseline to Month 12
percent changeMycophenolate Mofetil + SirolimusMycophenolate Mofetil + Cyclosporine or Tacrolimus
Baseline59.5 ± 23.8658.8 ± 26.06
Mean Percent Change from Baseline at Month 1224.4 ± 70.005.2 ± 56.33
Statistical analysis
  • Mycophenolate Mofetil + Sirolimus vs Mycophenolate Mofetil + Cyclosporine or Tacrolimus · ANCOVA · p = 0.012 (P value comparing the treatment groups calculated using ANCOVA model treatment and baseline calcineurin inhibitor (cyclosporine or tacrolimus) as factors and baseline measurement and time from transplant to randomization as covariates.) · Median difference (net): 18.7 · 95% CI 4.2 to 33.2
SecondaryMean Percent Change in Glomerular Filtration Rate From Baseline to Month 24

A secondary efficacy endpoint was mean percent change in renal function from baseline to 24 months postrandomization, as measured by Glomerular Filtration Rate utilizing renal clearance of cold iothalamate. percent change= \[(Glomerular Filtration Rate at Month 24-Glomerular Filtration Rate at baseline)/Glomerular Filtration Rate at baseline\]\*100 percent.

Time frame:
Baseline to 24 months
Reported as:
Mean · percent change
Mean Percent Change in Glomerular Filtration Rate From Baseline to Month 24
percent changeMycophenolate Mofetil + SirolimusMycophenolate Mofetil + Cyclosporine or Tacrolimus
Baseline59.5 ± 23.8658.8 ± 26.06
Percent Change from Baseline at Month 248.6 ± 55.323.4 ± 67.28
Statistical analysis
  • Mycophenolate Mofetil + Sirolimus vs Mycophenolate Mofetil + Cyclosporine or Tacrolimus · ANCOVA · p = 0.543 (P value comparing the treatment groups calculated using ANCOVA model treatment and baseline calcineurin inhibitor (cyclosporine or tacrolimus) type as factors and baseline measurement and time from transplant to randomization as covariates.) · Mean difference (net): 4.3 · 95% CI -9.6 to 18.2
SecondaryMean Percent Change in Serum Creatinine From Baseline to Months 6, 12, and 24

Renal allograft function determined by mean percent change from baseline in serum creatinine by treatment group at 6, 12, and 24 months postrandomization. percent change= \[(serum creatinine at Month t-serum creatinine at baseline)/serum creatinine at baseline\]\*100 percent, where t=6, 12, and 24 months postrandomization.

Time frame:
baseline, 6, 12, and 24 months
Reported as:
Mean · percent change
Mean Percent Change in Serum Creatinine From Baseline to Months 6, 12, and 24
percent changeMycophenolate Mofetil + SirolimusMycophenolate Mofetil + Cyclosporine or Tacrolimus
Baseline121.1 ± 29.96124.4 ± 37.87
Percent Change from Baseline at Month 6-3.7 ± 18.786.6 ± 34.61
Percent Change from Baseline at Month 126.0 ± 57.8120.4 ± 92.81
Percent Change from Baseline at Month 246.1 ± 59.8430.8 ± 114.23
Statistical analysis
  • Mycophenolate Mofetil + Sirolimus vs Mycophenolate Mofetil + Cyclosporine or Tacrolimus · ANCOVA · p = 0.003 (P value comparing the two treatment groups is calculated using ANCOVA with treatment and baseline calcineurin inhibitor type (cyclosporine or tacrolimus) as factors, and baseline measurement and time from transplant to randomization as covariates.) · Median difference (net): -10.8 · 95% CI -17.9 to -3.7
  • Mycophenolate Mofetil + Sirolimus vs Mycophenolate Mofetil + Cyclosporine or Tacrolimus · ANCOVA · p = 0.108 (P value comparing the two treatment groups is calculated using ANCOVA with treatment and baseline calcineurin inhibitor type (cyclosporine or tacrolimus) as factors, and baseline measurement and time from transplant to randomization as covariates.) · Mean difference (net): -16.0 · 95% CI -35.4 to 3.5
  • Mycophenolate Mofetil + Sirolimus vs Mycophenolate Mofetil + Cyclosporine or Tacrolimus · ANCOVA · p = 0.039 (P value comparing the two treatment groups is calculated using ANCOVA with treatment and baseline calcineurin inhibitor type (cyclosporine or tacrolimus) as factors, and baseline measurement and time from transplant to randomization as covariates.) · Mean difference (net): -24.4 · 95% CI -47.7 to -1.2
SecondaryMean Percent Change in Calculated Creatinine Clearance From Baseline to Months 6, 12, and 24

Renal allograft function determined by mean percent change from baseline in calculated creatinine clearance (Cockroft and Gault method) by treatment group at 6, 12, and 24 months postrandomization. percent change= \[(calculated creatinine clearance at Month t - calculated creatinine clearance at baseline)/calculated creatinine clearance at baseline\]\*100 percent, where t=6, 12, and 24 months postrandomization

Time frame:
baseline 6, 12, and 24 months
Reported as:
Mean · percent change
Mean Percent Change in Calculated Creatinine Clearance From Baseline to Months 6, 12, and 24
percent changeMycophenolate Mofetil + SirolimusMycophenolate Mofetil + Cyclosporine or Tacrolimus
Baseline59.7 ± 16.8560.5 ± 19.97
Percent Change from Baseline at Month 67.0 ± 19.54-1.7 ± 17.22
Percent Change from Baseline at Month 124.4 ± 24.38-2.3 ± 25.09
Percent Change from Baseline at Month 244.7 ± 27.58-4.2 ± 27.66
Statistical analysis
  • Mycophenolate Mofetil + Sirolimus vs Mycophenolate Mofetil + Cyclosporine or Tacrolimus · ANCOVA · p = <0.001 (P value comparing the two treatment groups is calculated using ANCOVA with treatment and baseline calcineurin inhibitor type (cyclosporine or tacrolimus) as factors, and baseline measurement and time from transplant to randomization as covariates.) · Mean difference (net): 8.7 · 95% CI 4.1 to 13.3
  • Mycophenolate Mofetil + Sirolimus vs Mycophenolate Mofetil + Cyclosporine or Tacrolimus · ANCOVA · p = 0.029 (P value comparing the two treatment groups is calculated using ANCOVA with treatment and baseline calcineurin inhibitor type (cyclosporine or tacrolimus) as factors, and baseline measurement and time from transplant to randomization as covariates.) · Mean difference (net): 6.9 · 95% CI 0.7 to 13.1
  • Mycophenolate Mofetil + Sirolimus vs Mycophenolate Mofetil + Cyclosporine or Tacrolimus · ANCOVA · p = 0.015 (P value comparing the two treatment groups is calculated using ANCOVA with treatment and baseline calcineurin inhibitor type (cyclosporine or tacrolimus) as factors, and baseline measurement and time from transplant to randomization as covariates.) · Mean difference (net): 8.8 · 95% CI 1.7 to 15.9
SecondaryMean Percent Change in Calculated Glomerular Filtration Rate From Baseline to Months 6, 12, and 24 (Nankivell Equation)

Renal allograft function determined by mean percent change from baseline in calculated Glomerular Filtration Rate (Nankivell equation) by treatment group at 6, 12, and 24 months postrandomization. percent change= \[(calculated Glomerular Filtration Rate at Month t - calculated Glomerular Filtration Rate at baseline)/calculated Glomerular Filtration Rate at baseline\]\*100 percent, where t=6, 12, and 24 months postrandomization.

Time frame:
baseline, 6, 12, and 24 months
Reported as:
Mean · percent change
Mean Percent Change in Calculated Glomerular Filtration Rate From Baseline to Months 6, 12, and 24 (Nankivell Equation)
percent changeMycophenolate Mofetil + SirolimusMycophenolate Mofetil + Cyclosporine or Tacrolimus
Baseline71.3 ± 13.8272.7 ± 16.2
Percent Change from Baseline at Month 68.3 ± 19.57-0.5 ± 15.98
Percent Change from Baseline at Month 125.2 ± 25.33-0.9 ± 23.42
Percent Change from Baseline at Month 246.5 ± 28.43-1.8 ± 27.31
Statistical analysis
  • Mycophenolate Mofetil + Sirolimus vs Mycophenolate Mofetil + Cyclosporine or Tacrolimus · ANCOVA · p = <0.001 (P value comparing the two treatment groups is calculated using ANCOVA with treatment and baseline calcineurin inhibitor type (cyclosporine or tacrolimus) as factors, and baseline measurement and time from transplant to randomization as covariates.) · Mean difference (net): 8.5 · 95% CI 4.2 to 12.9
  • Mycophenolate Mofetil + Sirolimus vs Mycophenolate Mofetil + Cyclosporine or Tacrolimus · ANCOVA · p = 0.059 (P value comparing the two treatment groups is calculated using ANCOVA with treatment and baseline calcineurin inhibitor type (cyclosporine or tacrolimus) as factors, and baseline measurement and time from transplant to randomization as covariates.) · Mean difference (net): 5.8 · 95% CI -0.2 to 11.9
  • Mycophenolate Mofetil + Sirolimus vs Mycophenolate Mofetil + Cyclosporine or Tacrolimus · ANCOVA · p = 0.036 (P value comparing the two treatment groups is calculated using ANCOVA with treatment and baseline calcineurin inhibitor type (cyclosporine or tacrolimus) as factors, and baseline measurement and time from transplant to randomization as covariates.) · Mean difference (net): 7.5 · 95% CI 0.5 to 14.5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mycophenolate Mofetil + Sirolimus—60/148 (40.5%)147/148 (99.3%)
Mycophenolate Mofetil + Cyclosporine or Tacrolimus—64/153 (41.8%)148/153 (96.7%)
Most frequent serious events
Showing 10 of 144
Most frequent serious events
EventMycophenolate Mofetil + SirolimusMycophenolate Mofetil + Cyclosporine or Tacrolimus
PneumoniaInfections and infestations14/1489/153
Urinary Tract InfectionInfections and infestations5/1488/153
PyelonephritisInfections and infestations4/1483/153
CellulitisInfections and infestations4/1481/153
Chest PainGeneral disorders4/1483/153
PyrexiaGeneral disorders4/1483/153
UrosepsisInfections and infestations3/1482/153
Basal Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/1483/153
Deep Vein ThrombosisVascular disorders3/1481/153
Abdominal PainGastrointestinal disorders1/1483/153
Most frequent other events
Showing 10 of 48
Most frequent other events
EventMycophenolate Mofetil + SirolimusMycophenolate Mofetil + Cyclosporine or Tacrolimus
DiarrhoeaGastrointestinal disorders51/14850/153
HyperlipidaemiaMetabolism and nutrition disorders44/14820/153
Oedema PeripheralGeneral disorders42/14820/153
LeukopeniaBlood and lymphatic system disorders36/14829/153
Urinary Tract InfectionInfections and infestations22/14833/153
HypertensionVascular disorders30/14825/153
Blood Creatinine IncreasedInvestigations14/14831/153
AnaemiaBlood and lymphatic system disorders25/14817/153
Upper Respiratory Tract InfectionInfections and infestations21/14819/153
Mouth UlcerationGastrointestinal disorders21/1480/153

Baseline characteristics

Age Continuous
Age Continuous(years)Mycophenolate Mofetil + SirolimusMycophenolate Mofetil + Cyclosporine or TacrolimusTotal
Mean48.7 ± 12.9048.7 ± 12.7048.7 ± 12.80
Sex: Female, Male
Sex: Female, Male(Participants)Mycophenolate Mofetil + SirolimusMycophenolate Mofetil + Cyclosporine or TacrolimusTotal
Female5555110
Male9396189
08

Study locations

36 sites
  • Bakersfield, California 93309, United States
  • Los Angeles, California 90033, United States
  • Los Angeles, California 90057, United States
  • Palo Alto, California 94304-1509, United States
  • Riverside, California 92501, United States
  • San Diego, California 92123, United States
  • San Francisco, California 94115, United States
  • Denver, Colorado 80262, United States
  • Hartford, Connecticut 06106-3316, United States
  • Washington, District of Columbia 20010-2975, United States
  • Atlanta, Georgia 30322, United States
  • Maywood, Illinois 60153, United States
  • Indianapolis, Indiana 46202-5124, United States
  • Indianapolis, Indiana 46202, United States
  • Iowa City, Iowa 52242, United States
  • Lexington, Kentucky 40536-0293, United States
  • New Orleans, Louisiana 70112, United States
  • Baltimore, Maryland 21201, United States
  • Boston, Massachusetts 02114-2696, United States
  • Detroit, Michigan 48202-2689, United States
  • Camden, New Jersey 08103, United States
  • Livingston, New Jersey 07039, United States
  • New York, New York 10029, United States
  • New York, New York 10032, United States
  • Durham, North Carolina 27710, United States
  • Cincinnati, Ohio 45267-0558, United States
  • Portland, Oregon 97201, United States
  • Philadelphia, Pennsylvania 19107, United States
  • Charleston, South Carolina 29425, United States
  • Sioux Falls, South Dakota 57105, United States
  • Memphis, Tennessee 38104, United States
  • Nashville, Tennessee 37232, United States
  • Dallas, Texas 75246, United States
  • Galveston, Texas 77555, United States
  • San Antonio, Texas 78284, United States
  • Charlottesville, Virginia 22908, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2005
First posted
Jul 21, 2005
Start
Aug 2003
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results first posted
Feb 24, 2011
Last update
Apr 15, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00121810
Lead sponsor
Hoffmann-La Roche
First posted
Jul 21, 2005
Start date
Aug 2003
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Feb 24, 2011
Last update
Apr 15, 2011

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion